A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
This important international study, called GBM AGILE, is looking for better ways to treat a serious type of brain cancer known as glioblastoma. It's designed to test several different medications at the same time for people who have been newly diagnosed or whose cancer has returned. The goal is to discover which treatments work best for different people with glioblastoma and to speed up the process of finding new and effective therapies. By carefully studying how patients respond, researchers hope to improve future care for this challenging condition.
At a glance
What is this study about?
This study, called GBM AGILE, is an international effort to find more effective treatments for a type of brain cancer called glioblastoma. Glioblastoma can be very difficult to treat, so researchers are always looking for new and better options. This trial is special because it's designed to test many different drugs and drug combinations at the same time, using a clever system to quickly identify which ones show promise.
Think of it like a smart testing ground where different treatments are being evaluated side-by-side. The study carefully watches how patients respond to each treatment. If a treatment seems to be working well, more patients might get the chance to try it. If one isn't effective, it can be stopped earlier, allowing researchers to focus on more promising options. This flexible approach helps speed up the discovery of new therapies.
The main goal is to improve the survival of people with glioblastoma. This includes those who have just been diagnosed and those whose cancer has come back after previous treatment. By learning which treatments work best for different groups of patients, doctors hope to offer more personalised and effective care in the future.
Key takeaways
- This is an international study testing new treatments for glioblastoma.
- It aims to find better ways to treat both newly diagnosed and recurrent glioblastoma.
- Multiple drugs are tested efficiently and simultaneously.
- Your general health and specific cancer details are checked for eligibility.
- Participation involves regular check-ups, scans, and taking the assigned medication.
- You can leave the study at any time without affecting your medical care.
Who may be eligible?
To join this study, you must be at least 18 years old and have a confirmed diagnosis of glioblastoma (brain cancer). Your medical team will need to check your specific diagnosis details to ensure they match the study's requirements.
If you've been newly diagnosed, you can't have had any past treatments for your glioblastoma, such as certain wafers, injections into the brain, radiation, or chemotherapy. If your glioblastoma has come back after treatment, you will need to have proof that the disease has progressed using specific scan results. For both groups, doctors will also check your general health and how well you can carry out daily activities to make sure you're well enough to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of glioblastoma?
- If newly diagnosed, have you had previous treatments for your glioblastoma, like certain wafers, injections, radiation, or chemotherapy?
- If your glioblastoma has returned, do you have recent scans showing the cancer has progressed?
- Are you generally well enough to participate in daily activities as assessed by your doctor?
What does participation involve?
If you decide to take part in this study, the specific details of what you'll do will depend on which treatment group you are assigned to. You will receive one of the study medications, which could involve taking pills, injections, or other forms of treatment. You will also have regular appointments, which will likely include physical exams, blood tests, and MRI brain scans to monitor your health and how the treatment is working. The total duration of your participation will vary depending on your treatment and how you respond, but the study aims to closely follow your progress to gather important information about the effectiveness and safety of the treatments.
Potential risks and benefits
Locations (63)
- University of Alabama at BirminghamVerified postcodeBirmingham, United States· Recruiting
- University of California, San DiegoVerified postcodeLa Jolla, United States· Recruiting
- Cedars Sinai - Samuel Oschin Comprehensive Cancer InstituteVerified postcodeLos Angeles, United States· Recruiting
- University of California, Los AngelesVerified postcodeLos Angeles, United States· Recruiting
- St. Joseph HospitalVerified postcodeOrange, United States· Recruiting
- University of California, San FranciscoVerified postcodeSan Francisco, United States· Recruiting
- Stanford Cancer CenterVerified postcodeStanford, United States· Completed
- University of Colorado DenverVerified postcodeAurora, United States· Recruiting
- Yale Cancer Center / Smilow Cancer Hospital*Verified postcodeNew Haven, United States· Recruiting
- Mayo Clinic Cancer CenterVerified postcodeJacksonville, United States· Completed
- Sylvester Comprehensive Cancer Center*Verified postcodeMiami, United States· Recruiting
- Moffitt Cancer CenterVerified postcodeTampa, United States· Recruiting
Common questions
What is glioblastoma?
Glioblastoma is a serious and aggressive type of brain cancer. This study is looking for better ways to treat it.
What kind of treatments are being tested?
The study is testing several different drugs, some of which are already used and some that are new. They can involve pills, injections, or special treatments like radiation.
Will I know which treatment I'm getting?
In some parts of the study, you might not know exactly which treatment you're getting until after the study is over. This helps researchers get unbiased results. Your doctor will explain this in more detail.
How long will I be in the study?
The length of your participation will depend on the specific treatment and how you respond. Your doctors will discuss the expected timeframe with you.
What happens after the study ends for me?
Once your participation concludes, your medical team will help you transition to ongoing care or further treatment options, based on your individual needs and the study results.
How to find out more
Patient Information
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.